Model for End-Stage Liver Disease

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

WikiDoc Resources for Model for End-Stage Liver Disease
Articles
Most recent articles on Model for End-Stage Liver Disease Most cited articles on Model for End-Stage Liver Disease Review articles on Model for End-Stage Liver Disease Articles on Model for End-Stage Liver Disease in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Model for End-Stage Liver Disease Images of Model for End-Stage Liver Disease Photos of Model for End-Stage Liver Disease Podcasts & MP3s on Model for End-Stage Liver Disease Videos on Model for End-Stage Liver Disease
Evidence Based Medicine
Cochrane Collaboration on Model for End-Stage Liver Disease Bandolier on Model for End-Stage Liver Disease TRIP on Model for End-Stage Liver Disease
Clinical Trials
Ongoing Trials on Model for End-Stage Liver Disease at Clinical Trials.gov Trial results on Model for End-Stage Liver Disease Clinical Trials on Model for End-Stage Liver Disease at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Model for End-Stage Liver Disease NICE Guidance on Model for End-Stage Liver Disease NHS PRODIGY Guidance FDA on Model for End-Stage Liver Disease CDC on Model for End-Stage Liver Disease
Books
Books on Model for End-Stage Liver Disease
News
Model for End-Stage Liver Disease in the news Be alerted to news on Model for End-Stage Liver Disease News trends on Model for End-Stage Liver Disease
Commentary
Blogs on Model for End-Stage Liver Disease
Definitions
Definitions of Model for End-Stage Liver Disease
Patient Resources / Community
Patient resources on Model for End-Stage Liver Disease Discussion groups on Model for End-Stage Liver Disease Patient Handouts on Model for End-Stage Liver Disease Directions to Hospitals Treating Model for End-Stage Liver Disease Risk calculators and risk factors for Model for End-Stage Liver Disease
Healthcare Provider Resources
Symptoms of Model for End-Stage Liver Disease Causes & Risk Factors for Model for End-Stage Liver Disease Diagnostic studies for Model for End-Stage Liver Disease Treatment of Model for End-Stage Liver Disease
Continuing Medical Education (CME)
CME Programs on Model for End-Stage Liver Disease
International
Model for End-Stage Liver Disease en Espanol Model for End-Stage Liver Disease en Francais
Business
Model for End-Stage Liver Disease in the Marketplace Patents on Model for End-Stage Liver Disease
Experimental / Informatics
List of terms related to Model for End-Stage Liver Disease

The Model for End-Stage Liver Disease, or MELD, is a scoring system for assessing the severity of chronic liver disease. It was initially described by Kamath et al in 2001 and modified by Wiesner et al, also in 2001.

It uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. This score is also used by the United Network for Organ Sharing (UNOS) and Eurotransplant for prioritizing allocation of liver transplants.

It is calculated according to the following formula:

MELD = 3.78[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.57[Ln serum creatinine (mg/dL)] + 6.43

Caveats with the score include:

• The maximum score given for MELD is 40. All values higher than 40 are given a score of 40
• If the patient has been dialyzed twice within the last 7 days, then the value for serum creatinine used should be 4.0
• Any value less than one is given a value of 1 (i.e. if bilirubin is 0.8, a value of 1.0 is used).

PATIENTS WITH LIVER CANCER Patients with a diagnosis of liver cancer will be assigned a MELD score based on how advanced the cancer is. This staging system is known as the TNM. T stands for the extent of the tumor, N stands for the presence or absence of lymph nodes, and M stands for the presence or absence of metastasis (tumor spread to another organ such as the lung in the case of liver cancer).

References

• Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR (2001). "A model to predict survival in patients with end-stage liver disease". Hepatology. 33 (2): 464–70. PMID 11172350.CS1 maint: Multiple names: authors list (link)
• Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, Kim WR (2001). "MELD and PELD: application of survival models to liver allocation". Liver Transpl. 7 (7): 567–80. PMID 11460223.CS1 maint: Multiple names: authors list (link)
• Melissa Palmer, MD ," Dr. Melissa Palmer's Guide of Hepatitis and Liver Disease". (Published 2004. Penguin Putnam).
• More information about the MELD/PELD calculation, UNOS [2]

See also

• Pediatric End-Stage Liver Disease

External links

Online calculator for MELD score/UNOS modification: [3]